Answers are grounded in this paper and cite their sources.
A 59-year-old Filipino man who had been treated for metastatic renal cell carcinoma with two doses of a ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP or Triapine), presented with marked cyanosis, headache, dizziness and exertional dyspnoea that had developed over an 8 h period. His peripheral O2 saturation was 64%, pO2 was normal, arterial O2 saturation was 83%, and methaemoglobin level was 35%. Haemoglobin was 13·9 g/dl, bilirubin was 72 μmol/l, lactate dehydrogenase was 372 U/l and haptoglobin was <0·09 g/l. The patient was treated with methylene blue for methaemoglobinaemia without success. The patient's plasma (top, left tube) was red-brown in colour [in contrast to haemolysed (top, centre tube) and normal (top, right tube) plasma] due to methaemoglobin, and a blood film (bottom) showed oxidative haemolysis with many blister and bite cells (arrows), spherocytes (double arrows), ghost cells (arrowhead) and coarse basophilic stippling (double arrowheads). Glucose 6-phosphate dehydrogenase activity was <1%. 3-AP and methylene blue were discontinued, and the patient recovered uneventfully with hydration, erythrocyte transfusions and oxygen supplementation. Bakul I. Dalal 1 and Christian Kollmannsberger 2 1 Division of Hematopathology, Vancouver General Hospital , 2 Division of Medical Oncology, Vancouver Cancer Center/BC Cancer Agency, Vancouver, BC, Canada. E-mail: bdalal@vanhosp.bc.ca
No takes yet. Share an insight, caveat, or question.
Dalal et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: